Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions
Anna L. Blobaum, Thomas M. Bridges, Frank W. Byers, Mark L. Turlington, Margrith E. Mattmann, Ryan D. Morrison, Claire Mackie, Hilde Lavreysen, José M. Bartolomé, Gregor J. MacDonald, Thomas Steckler, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer and J. Scott Daniels
Drug Metabolism and Disposition December 2013, 41 (12) 2066-2075; DOI: https://doi.org/10.1124/dmd.113.052662
Anna L. Blobaum
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Thomas M. Bridges
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Frank W. Byers
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Mark L. Turlington
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Margrith E. Mattmann
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Ryan D. Morrison
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Claire Mackie
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Hilde Lavreysen
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
José M. Bartolomé
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Gregor J. MacDonald
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Thomas Steckler
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Carrie K. Jones
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Colleen M. Niswender
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
P. Jeffrey Conn
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Craig W. Lindsley
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
Shaun R. Stauffer
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)
J. Scott Daniels
Drug Metabolism and Pharmacokinetics Laboratory (A.L.B., T.M.B., F.W.B., R.D.M., J.S.D.), Medicinal Chemistry Laboratory (M.L.T., M.E.M., C.W.L., S.R.S.), and Molecular Pharmacology Laboratory (C.K.J., C.M.N., P.J.C.), Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, Tennessee; CREATe ADME/Tox, (C.M.), and Neuroscience (H.L., G.J.M., T.S.), Janssen Research and Development, Beerse, Belgium; and Jarama 75, Toledo, Spain (J.M.B.)

DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Heterotropic Activation of CYP3A by a Novel mGlu5 PAM
Anna L. Blobaum, Thomas M. Bridges, Frank W. Byers, Mark L. Turlington, Margrith E. Mattmann, Ryan D. Morrison, Claire Mackie, Hilde Lavreysen, José M. Bartolomé, Gregor J. MacDonald, Thomas Steckler, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer and J. Scott Daniels
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2066-2075; DOI: https://doi.org/10.1124/dmd.113.052662
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems
Heterotropic Activation of CYP3A by a Novel mGlu5 PAM
Anna L. Blobaum, Thomas M. Bridges, Frank W. Byers, Mark L. Turlington, Margrith E. Mattmann, Ryan D. Morrison, Claire Mackie, Hilde Lavreysen, José M. Bartolomé, Gregor J. MacDonald, Thomas Steckler, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer and J. Scott Daniels
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2066-2075; DOI: https://doi.org/10.1124/dmd.113.052662
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement